Is MRNA or MGX more profitable?

Moderna has a net margin of -141.43% compared to Metagenomi's net margin of -384.61%. Moderna's return on equity of -28.30% beat Metagenomi's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Metagenomi -384.61% -63.65% -44.52%

Does the media prefer MRNA or MGX?

In the previous week, Moderna had 20 more articles in the media than Metagenomi. MarketBeat recorded 23 mentions for Moderna and 3 mentions for Metagenomi. Metagenomi's average media sentiment score of 1.60 beat Moderna's score of 0.46 indicating that Metagenomi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 7 Very Positive mention(s) 9 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Metagenomi 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is MGX or MDWD more profitable?

MediWound has a net margin of -170.10% compared to Metagenomi's net margin of -384.61%. MediWound's return on equity of -47.24% beat Metagenomi's return on equity. Company Net Margins Return on Equity Return on Assets Metagenomi -384.61% -63.65% -44.52% MediWound -170.10% -47.24% -24.27%

Does the media refer more to MGX or MDWD?

In the previous week, MediWound had 1 more articles in the media than Metagenomi. MarketBeat recorded 4 mentions for MediWound and 3 mentions for Metagenomi. MediWound's average media sentiment score of 1.89 beat Metagenomi's score of 1.60 indicating that MediWound is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MediWound 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer SPRB or MGX?

In the previous week, Metagenomi had 1 more articles in the media than Spruce Biosciences. MarketBeat recorded 3 mentions for Metagenomi and 2 mentions for Spruce Biosciences. Metagenomi's average media sentiment score of 1.60 beat Spruce Biosciences' score of 0.93 indicating that Metagenomi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Metagenomi 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to ADCT or MGX?

In the previous week, ADC Therapeutics and ADC Therapeutics both had 3 articles in the media. Metagenomi's average media sentiment score of 1.60 beat ADC Therapeutics' score of 0.56 indicating that Metagenomi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Metagenomi 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Metagenomi (MGX) Competitors

$1.20 +0.04 (+3.02%)

As of 12:40 PM Eastern

Compare

MGX vs. MRNA, MDWD, MOLN, SPRB, and ADCT

Should you buy Metagenomi stock or one of its competitors? Metagenomi's main competitors and comparable companies include Moderna (MRNA), MediWound (MDWD), Molecular Partners (MOLN), Spruce Biosciences (SPRB), and ADC Therapeutics (ADCT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Metagenomi compare to Moderna?

Moderna (NASDAQ:MRNA) and Metagenomi (NASDAQ:MGX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Metagenomi has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	30.12	-$2.82B	-$7.99	N/A
Metagenomi	$25.21M	1.79	-$87.87M	-$2.49	N/A

Moderna currently has a consensus target price of $76.72, suggesting a potential downside of 47.70%. Metagenomi has a consensus target price of $6.00, suggesting a potential upside of 402.09%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

75.3% of Moderna shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 12.5% of Metagenomi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Moderna has a net margin of -141.43% compared to Metagenomi's net margin of -384.61%. Moderna's return on equity of -28.30% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Metagenomi	-384.61%	-63.65%	-44.52%

Moderna has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

In the previous week, Moderna had 20 more articles in the media than Metagenomi. MarketBeat recorded 23 mentions for Moderna and 3 mentions for Metagenomi. Metagenomi's average media sentiment score of 1.60 beat Moderna's score of 0.46 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	7 Very Positive mention(s)	9 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Metagenomi	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Moderna beats Metagenomi on 9 of the 17 factors compared between the two stocks.

How does Metagenomi compare to MediWound?

Metagenomi (NASDAQ:MGX) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

In the previous week, MediWound had 1 more articles in the media than Metagenomi. MarketBeat recorded 4 mentions for MediWound and 3 mentions for Metagenomi. MediWound's average media sentiment score of 1.89 beat Metagenomi's score of 1.60 indicating that MediWound is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MediWound	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

MediWound has lower revenue, but higher earnings than Metagenomi. MediWound is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.79	-$87.87M	-$2.49	N/A
MediWound	$16.96M	10.36	-$23.88M	-$1.80	N/A

MediWound has a net margin of -170.10% compared to Metagenomi's net margin of -384.61%. MediWound's return on equity of -47.24% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-63.65%	-44.52%
MediWound	-170.10%	-47.24%	-24.27%

Metagenomi has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, MediWound has a beta of 0.14, meaning that its stock price is 86% less volatile than the broader market.

Metagenomi presently has a consensus target price of $6.00, indicating a potential upside of 402.09%. MediWound has a consensus target price of $33.00, indicating a potential upside of 141.42%. Given Metagenomi's stronger consensus rating and higher probable upside, equities research analysts clearly believe Metagenomi is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

46.8% of MediWound shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by company insiders. Comparatively, 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

MediWound beats Metagenomi on 9 of the 16 factors compared between the two stocks.

How does Metagenomi compare to Molecular Partners?

Molecular Partners (NASDAQ:MOLN) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Molecular Partners has higher earnings, but lower revenue than Metagenomi. Molecular Partners is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Molecular Partners	$5.65M	29.66	-$74.41M	-$1.71	N/A
Metagenomi	$25.21M	1.79	-$87.87M	-$2.49	N/A

Molecular Partners currently has a consensus price target of $8.38, indicating a potential upside of 101.81%. Metagenomi has a consensus price target of $6.00, indicating a potential upside of 402.09%. Given Metagenomi's stronger consensus rating and higher probable upside, analysts plainly believe Metagenomi is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Metagenomi had 2 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Metagenomi and 1 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 1.87 beat Metagenomi's score of 1.60 indicating that Molecular Partners is being referred to more favorably in the media.

Company	Overall Sentiment
Molecular Partners	Very Positive
Metagenomi	Very Positive

26.6% of Molecular Partners shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by insiders. Comparatively, 12.5% of Metagenomi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Molecular Partners has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Molecular Partners	N/A	-68.36%	-54.82%
Metagenomi	-384.61%	-63.65%	-44.52%

Molecular Partners has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Summary

Metagenomi beats Molecular Partners on 9 of the 16 factors compared between the two stocks.

How does Metagenomi compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

91.7% of Spruce Biosciences shares are owned by institutional investors. 4.3% of Spruce Biosciences shares are owned by company insiders. Comparatively, 12.5% of Metagenomi shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Metagenomi had 1 more articles in the media than Spruce Biosciences. MarketBeat recorded 3 mentions for Metagenomi and 2 mentions for Spruce Biosciences. Metagenomi's average media sentiment score of 1.60 beat Spruce Biosciences' score of 0.93 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Metagenomi	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Spruce Biosciences has higher earnings, but lower revenue than Metagenomi. Spruce Biosciences is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	32.61	-$38.97M	-$39.78	N/A
Metagenomi	$25.21M	1.79	-$87.87M	-$2.49	N/A

Spruce Biosciences currently has a consensus target price of $159.50, suggesting a potential upside of 185.87%. Metagenomi has a consensus target price of $6.00, suggesting a potential upside of 402.09%. Given Metagenomi's higher probable upside, analysts clearly believe Metagenomi is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Spruce Biosciences has a beta of 3.31, meaning that its stock price is 231% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Spruce Biosciences has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-123.53%	-90.35%
Metagenomi	-384.61%	-63.65%	-44.52%

Summary

Metagenomi beats Spruce Biosciences on 10 of the 16 factors compared between the two stocks.

How does Metagenomi compare to ADC Therapeutics?

ADC Therapeutics (NYSE:ADCT) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Metagenomi has lower revenue, but higher earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.73	-$142.62M	-$0.66	N/A
Metagenomi	$25.21M	1.79	-$87.87M	-$2.49	N/A

ADC Therapeutics has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

ADC Therapeutics presently has a consensus target price of $5.00, indicating a potential upside of 352.49%. Metagenomi has a consensus target price of $6.00, indicating a potential upside of 402.09%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than ADC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

ADC Therapeutics has a net margin of -121.77% compared to Metagenomi's net margin of -384.61%. ADC Therapeutics' return on equity of 0.00% beat Metagenomi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-121.77%	N/A	-32.74%
Metagenomi	-384.61%	-63.65%	-44.52%

41.1% of ADC Therapeutics shares are owned by institutional investors. 5.1% of ADC Therapeutics shares are owned by company insiders. Comparatively, 12.5% of Metagenomi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, ADC Therapeutics and ADC Therapeutics both had 3 articles in the media. Metagenomi's average media sentiment score of 1.60 beat ADC Therapeutics' score of 0.56 indicating that Metagenomi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Metagenomi	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

ADC Therapeutics and Metagenomi tied by winning 8 of the 16 factors compared between the two stocks.

Get Metagenomi News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGX vs. The Competition

Export

Metric	Metagenomi	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$45.15M	$3.89B	$7.21B	$12.75B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-0.48	14.90	274.47	25.48
Price / Sales	1.79	1,414.37	637.09	88.51
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	0.28	15.16	10.38	6.26
Net Income	-$87.87M	-$22.82M	$3.49B	$358.19M
7 Day Performance	2.14%	-1.72%	-2.11%	-1.31%
1 Month Performance	-2.85%	2.31%	0.52%	-2.59%
1 Year Performance	-35.75%	43.26%	24.69%	8.65%

Metagenomi Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGX Metagenomi	4.1949 of 5 stars	$1.20 +3.0%	$6.00 +402.1%	-37.6%	$45.15M	$25.21M	N/A	236
MRNA Moderna	2.1268 of 5 stars	$145.10 -0.3%	$76.72 -47.1%	+512.4%	$57.77B	$1.94B	N/A	4,700
MDWD MediWound	2.0987 of 5 stars	$13.54 +1.9%	$33.00 +143.8%	-26.5%	$174.63M	$16.96M	N/A	80	News Coverage
MOLN Molecular Partners	2.6243 of 5 stars	$4.22 -3.0%	$8.38 +98.4%	+13.4%	$170.44M	$5.65M	N/A	180	Positive News Gap Down
SPRB Spruce Biosciences	2.5427 of 5 stars	$58.94 +1.7%	$159.50 +170.6%	+333.1%	$169.16M	$4.91M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGX) was last updated on 9/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Metagenomi (MGX) Competitors

MGX vs. MRNA, MDWD, MOLN, SPRB, and ADCT

How does Metagenomi compare to Moderna?

Summary

How does Metagenomi compare to MediWound?

Summary

How does Metagenomi compare to Molecular Partners?

Summary

How does Metagenomi compare to Spruce Biosciences?

Summary

How does Metagenomi compare to ADC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX vs. The Competition

Metagenomi Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Metagenomi (MGX) Competitors

MGX vs. MRNA, MDWD, MOLN, SPRB, and ADCT

How does Metagenomi compare to Moderna?

Which has higher valuation and earnings, MRNA or MGX?

Do analysts rate MRNA or MGX?

Do insiders & institutionals believe in MRNA or MGX?

Is MRNA or MGX more profitable?

Which has more volatility and risk, MRNA or MGX?

Does the media prefer MRNA or MGX?

Summary

How does Metagenomi compare to MediWound?

Does the media refer more to MGX or MDWD?

Which has preferable earnings & valuation, MGX or MDWD?

Is MGX or MDWD more profitable?

Which has more risk and volatility, MGX or MDWD?

Do analysts recommend MGX or MDWD?

Do institutionals and insiders believe in MGX or MDWD?

Summary

How does Metagenomi compare to Molecular Partners?

Which has stronger valuation and earnings, MOLN or MGX?

Do analysts rate MOLN or MGX?

Does the media favor MOLN or MGX?

Do institutionals and insiders believe in MOLN or MGX?

Is MOLN or MGX more profitable?

Which has more risk & volatility, MOLN or MGX?

Summary

How does Metagenomi compare to Spruce Biosciences?

Do institutionals and insiders hold more shares of SPRB or MGX?

Does the media prefer SPRB or MGX?

Which has better earnings & valuation, SPRB or MGX?

Do analysts rate SPRB or MGX?

Which has more risk & volatility, SPRB or MGX?

Is SPRB or MGX more profitable?

Summary

How does Metagenomi compare to ADC Therapeutics?

Which has stronger valuation & earnings, ADCT or MGX?

Which has more risk and volatility, ADCT or MGX?

Do analysts recommend ADCT or MGX?

Is ADCT or MGX more profitable?

Do institutionals & insiders believe in ADCT or MGX?

Does the media refer more to ADCT or MGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX vs. The Competition

Metagenomi Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools